Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0B4BN
|
||||
| Former ID |
DNC003705
|
||||
| Drug Name |
Ro-60-0175
|
||||
| Synonyms |
Ro-600175
|
||||
| Drug Type |
Small molecular drug
|
||||
| Formula |
C11H12ClFN2
|
||||
| InChI |
InChI=1S/C11H12ClFN2/c1-7(14)6-15-3-2-8-4-10(13)9(12)5-11(8)15/h2-5,7H,6,14H2,1H3/t7-/m0/s1
|
||||
| InChIKey |
XJJZQXUGLLXTHO-ZETCQYMHSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 2A receptor | Target Info | Inhibitor | [529168] | |
| 5-hydroxytryptamine 2B receptor | Target Info | Inhibitor | [527833] | ||
| 5-hydroxytryptamine 2C receptor | Target Info | Inhibitor | [529168] | ||
| WikiPathways | Serotonin Receptor 2 and STAT3 Signaling | ||||
| Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
| SIDS Susceptibility Pathways | |||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, OtherWP732:Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
| GPCR downstream signalingWP732:Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
| References | |||||
| Ref 539026 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 166). | ||||
| Ref 546467 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008324) | ||||
| Ref 527833 | Bioorg Med Chem Lett. 2006 Feb;16(3):677-80. Epub 2005 Oct 27.Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists. | ||||
| Ref 529168 | Bioorg Med Chem. 2008 Feb 15;16(4):1966-82. Epub 2007 Nov 4.Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.